Palisade Bio Inc.(PALI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PALI Palisade Bio Inc.

Trading 11-22 09:49:54 EST

2.51

+0.07

+2.87%

High2.55	Low2.44	Vol9.19K
Open2.44	D1 Closing2.44	Amplitude4.51%
Mkt Cap3.34M	Tradable Cap3.28M	Total Shares1.33M
T/O22.76K	T/O Rate0.70%	Tradable Shares1.31M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"PALI","market":"US","secType":"STK","nameCN":"Palisade Bio Inc.","latestPrice":2.51,"timestamp":1732286827227,"preClose":2.44,"halted":0,"volume":9187,"delay":0,"floatShares":1308000,"shares":1329516,"eps":-18.252869,"marketStatus":"Trading","change":0.07,"latestTime":"11-22 09:49:54 EST","open":2.44,"high":2.55,"low":2.44,"amount":22760.673069,"amplitude":0.045082,"askPrice":2.58,"askSize":100,"bidPrice":2.51,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-18.252869,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732309200000},"marketStatusCode":2,"adr":0,"listingDate":1188187200000,"exchange":"NASDAQ","adjPreClose":2.44,"preHourTrading":{"tag":"盘前","latestPrice":2.44,"preClose":2.44,"latestTime":"09:26 EST","volume":911,"amount":2186.530273,"timestamp":1732285568585},"postHourTrading":{"tag":"盘后","latestPrice":2.44,"preClose":2.44,"latestTime":"16:40 EST","volume":5,"amount":12.1,"timestamp":1732225220911},"volumeRatio":2.028665},"requestUrl":"/m/hq/s/PALI/wiki","defaultTab":"wiki","newsList":[{"id":"2485441758","title":"BRIEF-Palisade Bio Inc - Offering 2.1 Million Shares At $2.43 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2485441758","media":"Reuters","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485441758?lang=en_us&edition=fundamental","pubTime":"2024-11-22 03:27","pubTimestamp":1732217265,"startTime":"0","endTime":"0","summary":"BRIEF-Palisade Bio Inc - Offering 2.1 Million Shares At $2.43 Per ShareNov 21 (Reuters) - Palisade Bio Inc PALI.O:PALISADE BIO INC - OFFERING 2.1 MILLION SHARES AT $2.43 PER SHARE ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MS0LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","PALI"],"gpt_icon":0},{"id":"2485441429","title":"Palisade Bio Inc - Offering 2.1 Mln Shares at $2.43 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2485441429","media":"THOMSON REUTERS","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485441429?lang=en_us&edition=fundamental","pubTime":"2024-11-22 03:22","pubTimestamp":1732216959,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MS0LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PALI","BK4007"],"gpt_icon":0},{"id":"2485503496","title":"Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2485503496","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485503496?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:15","pubTimestamp":1732194900,"startTime":"0","endTime":"0","summary":"Data to be presented at the 8th Annual Antifibrotic Drug Development (AFDD) Summit PALI-2108 may offer a solution for fibrostenotic Crohn’s disease by enhancing efficacy, safety, and therapeutic poten","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/21/2985196/0/en/Palisade-Bio-to-Present-Preclinical-Results-for-PALI-2108-Demonstrating-Engagement-of-Key-Fibrotic-Pathways-of-Crohn-s-Disease-and-Ulcerative-Colitis-UC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI"],"gpt_icon":0},{"id":"2485171216","title":"Palisade Bio Initiated at Buy by Brookline Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2485171216","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485171216?lang=en_us&edition=fundamental","pubTime":"2024-11-21 06:10","pubTimestamp":1732140600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PALI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2024 17:10 ET (22:10 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BRKL","BK4211","BK4139","PALI"],"gpt_icon":0},{"id":"2485512958","title":"Palisade Bio initiated with a Buy at Brookline","url":"https://stock-news.laohu8.com/highlight/detail?id=2485512958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485512958?lang=en_us&edition=fundamental","pubTime":"2024-11-21 02:26","pubTimestamp":1732127179,"startTime":"0","endTime":"0","summary":"Brookline initiated coverage of Palisade Bio (PALI) with a Buy rating and $38 price target Palisade Bio is advancing novel therapeutics for patient...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palisade-bio-initiated-with-a-buy-at-brookline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palisade-bio-initiated-with-a-buy-at-brookline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BRKL","BK4211","PALI"],"gpt_icon":0},{"id":"2483393078","title":"Palisade Bio Is Maintained at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2483393078","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483393078?lang=en_us&edition=fundamental","pubTime":"2024-11-14 00:38","pubTimestamp":1731515880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PALI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 11:38 ET (16:38 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI"],"gpt_icon":0},{"id":"2483504021","title":"U.S. RESEARCH ROUNDUP- AMN Healthcare Services, Chart Industries, Home Depot","url":"https://stock-news.laohu8.com/highlight/detail?id=2483504021","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483504021?lang=en_us&edition=fundamental","pubTime":"2024-11-13 15:03","pubTimestamp":1731481390,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AMN Healthcare Services, Chart Industries and Home Depot, on Wedn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IAC","BK4209","BK4224","BMY","LU0683600562.USD","SATS","KZR","LU2065171402.SGD","COLD","LU1430594728.SGD","LINE","ICUI","DAY","HD","LEGN","PT","AMN","NUVL","EVCM","GTLS","HRTX","FATE","CAVA","LNW","BHVN","INDP","BBIO","STIM","BK4533","MOS","ATLC","PALI","NVAX","IBP","LU0354030511.USD","HCAR","HSBC","HON","ITOS","LU1093756168.USD","BK4539","LU0820562030.AUD","CART","SHOP","BLFS","PRME","AXSM","PTVE","EWTX","DCOM"],"gpt_icon":1},{"id":"2483012637","title":"Palisade Bio Inc :  Maxim Group Cuts Target Price to $8 From $22.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2483012637","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483012637?lang=en_us&edition=fundamental","pubTime":"2024-11-13 11:55","pubTimestamp":1731470118,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nFWN3MJ1IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PALI","BK4139","BK4007"],"gpt_icon":0},{"id":"2482370224","title":"Palisade Bio Q3 EPS $(2.32) Beats $(3.35) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2482370224","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482370224?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:47","pubTimestamp":1731419252,"startTime":"0","endTime":"0","summary":"Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(2.32) per share which beat the analyst consensus estimate of $(3.35) by 30.75 percent. This is a 68.56 percent increase over losses of $(7.38) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41900491/palisade-bio-q3-eps-2-32-beats-3-35-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Palisade Bio Q3 EPS $(2.32) Beats $(3.35) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI"],"gpt_icon":0},{"id":"2482702080","title":"Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program Pali-2108","url":"https://stock-news.laohu8.com/highlight/detail?id=2482702080","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482702080?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:45","pubTimestamp":1731419100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nTUA21R7ZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PALI","BK4139","BK4007"],"gpt_icon":0},{"id":"2482027527","title":"Palisade Bio Inc: Qtrly Net Loss per Share $2.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2482027527","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482027527?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:45","pubTimestamp":1731419100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nTUA21R7ZC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","PALI"],"gpt_icon":0},{"id":"2482700878","title":"Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108","url":"https://stock-news.laohu8.com/highlight/detail?id=2482700878","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482700878?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:45","pubTimestamp":1731419100,"startTime":"0","endTime":"0","summary":"Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC) Carlsbad,CA, Nov.  12, 2024  (GLOBE NEWSWIRE) -- Palisade Bio, In","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2979222/0/en/Palisade-Bio-Reports-Third-Quarter-2024-Financial-Results-and-Outlines-Key-Accomplishments-and-Next-Steps-to-Advance-Lead-Program-PALI-2108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI"],"gpt_icon":0},{"id":"2481188830","title":"BRIEF-Palisade Bio Announces First Subject Dosed In Phase 1 Clinical Study Of Pali-2108 For The Treatment Of Moderate-To-Severe Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2481188830","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481188830?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:59","pubTimestamp":1730987955,"startTime":"0","endTime":"0","summary":"BRIEF-Palisade Bio Announces First Subject Dosed In Phase 1 Clinical Study Of Pali-2108 For The Treatment Of Moderate-To-Severe Ulcerative ColitisNov 7 (Reuters) - Palisade Bio Inc PALI.O:PALISADE BIO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUABPWJC6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PALI","BK4139"],"gpt_icon":0},{"id":"2481907844","title":"Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of Pali-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (Uc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481907844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481907844?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:30","pubTimestamp":1730986201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUABPWJC6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PALI","BK4139"],"gpt_icon":0},{"id":"2481690034","title":"Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481690034","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481690034?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:30","pubTimestamp":1730986200,"startTime":"0","endTime":"0","summary":"Carlsbad,CA, Nov.  07, 2024  (GLOBE NEWSWIRE) -- Palisade Bio, Inc.(Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/07/2976706/0/en/Palisade-Bio-Announces-First-Subject-Dosed-in-Phase-1-Clinical-Study-of-PALI-2108-for-the-Treatment-of-Moderate-to-Severe-Ulcerative-Colitis-UC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2265009873.SGD","BK4534","LU1169590202.USD","BK4023","BK4139","BK4181","LU1169589451.USD","LU1804176565.USD","ALC","BK4198","PD","PK","BK4218","PALI"],"gpt_icon":0},{"id":"2479620086","title":"Palisade Bio Announces Positive Data From Two Ex Vivo Translational Studies of Pali-2108 for the Treatment of Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2479620086","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479620086?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:30","pubTimestamp":1730377800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUA6DVVQQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PALI","BK4007"],"gpt_icon":0},{"id":"2479608902","title":"Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2479608902","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479608902?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:30","pubTimestamp":1730377800,"startTime":"0","endTime":"0","summary":"Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease . PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially enhancing patient compliance compared to existing PDE4 inhibitors. The poster titled “Colonic Bioactivation and Potent TNFα Inhibition of PALI-2108 in Human Clinical Studies: A Promising PDE4 Inhibitor Prodrug for the Oral Treatment of Ulcerative Colitis,” was presented by Dr. Mitch Jones, Chief Medical Officer of Palisade Bio, at the ACG 2024 Annual Scientific Meeting, held October 25-30, 2024, in Philadelphia, PA.“The design of PALI-2108 ensures that activation is targeted primarily in the colon, which should minimize systemic exposure and potential central nervous system side effects. By demonstrating reduced systemic exposure, we believe PALI-2108 can effectively address the toxicity issues commonly associated with other PDE4 inhibitors like roflumilast and apremilast,” stated Dr. Mitch","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9pRvRuURDlO1_YMCjSwOsw--~B/aD0xMTk7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/4986e16c7ba951018cc07b5956db4a27","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9pRvRuURDlO1_YMCjSwOsw--~B/aD0xMTk7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/4986e16c7ba951018cc07b5956db4a27"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palisade-bio-announces-positive-data-123000631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","IBD","PALI"],"gpt_icon":0},{"id":"2479733236","title":"Palisade Bio Files for Public Offering of Shares, Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2479733236","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479733236?lang=en_us&edition=fundamental","pubTime":"2024-10-30 23:33","pubTimestamp":1730302404,"startTime":"0","endTime":"0","summary":"Palisade Bio  on Wednesday filed a registration statement with the US Securities and Exchange Commission for a public offering of shares or pre-funded warrants.The actual size and pricing of the offering are yet to be determined.Pre-funded warrants will be offered to shareholders owning more than a 4.99% stake in the company after buying common shares under the offering. Each pre-funded warrant allows for one common share upon exercise, the company said.Palisade shares fell 8% in recent trading.Price: 3.11, Change: -0.27, Percent Change: -8.02","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","PALI","BK4139"],"gpt_icon":1},{"id":"2474820742","title":"Palisade Bio Gets Health Canada Clearance to Start Phase 1 Study of PALI-2108 for Treating Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2474820742","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474820742?lang=en_us&edition=fundamental","pubTime":"2024-10-10 22:29","pubTimestamp":1728570549,"startTime":"0","endTime":"0","summary":"Palisade Bio (PALI) said Thursday it has received clearance from Health Canada to start a phase 1 trial that will evaluate PALI-2108 for the treatment of ulcerative colitis.Preparations for the trial ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4007","PALI"],"gpt_icon":0},{"id":"2474371004","title":"BRIEF-Palisade Bio Cleared By Health Canada To Commence Phase 1 Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2474371004","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474371004?lang=en_us&edition=fundamental","pubTime":"2024-10-10 20:45","pubTimestamp":1728564322,"startTime":"0","endTime":"0","summary":"Oct 10  - Palisade Bio Inc   :   * PALISADE BIO CLEARED BY HEALTH CANADA TO COMMENCE PHASE 1 CLINICAL STUDY FOR LEAD PROGRAM, PALI-2108 FOR THE TREATMENT OF ULCERATIVE COLITIS    * PALISADE BIO INC - ON TRACK COMMENCE SITE INITIATION AND ENROLLMENT FOR STUDY BEFORE YEAR ENDSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PALI","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.palisadebio.com","stockEarnings":[{"period":"1week","weight":-0.0687},{"period":"1month","weight":-0.3405},{"period":"3month","weight":-0.2886},{"period":"6month","weight":-0.5031},{"period":"1year","weight":-0.7192},{"period":"ytd","weight":-0.7243}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.611111,"avgChangeRate":0.033511},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.023449},{"month":3,"riseRate":0.5,"avgChangeRate":0.019892},{"month":4,"riseRate":0.388889,"avgChangeRate":-0.052938},{"month":5,"riseRate":0.277778,"avgChangeRate":-0.08806},{"month":6,"riseRate":0.277778,"avgChangeRate":-0.04844},{"month":7,"riseRate":0.388889,"avgChangeRate":-0.119663},{"month":8,"riseRate":0.388889,"avgChangeRate":-0.07448},{"month":9,"riseRate":0.5,"avgChangeRate":0.062425},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.11049},{"month":11,"riseRate":0.388889,"avgChangeRate":-0.003137},{"month":12,"riseRate":0.470588,"avgChangeRate":0.034302}],"exchange":"NASDAQ","name":"Palisade Bio Inc.","nameEN":"Palisade Bio Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Palisade Bio Inc.(PALI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Palisade Bio Inc.(PALI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Palisade Bio Inc.,PALI,Palisade Bio Inc.股票,Palisade Bio Inc.股票老虎,Palisade Bio Inc.股票老虎国际,Palisade Bio Inc.行情,Palisade Bio Inc.股票行情,Palisade Bio Inc.股价,Palisade Bio Inc.股市,Palisade Bio Inc.股票价格,Palisade Bio Inc.股票交易,Palisade Bio Inc.股票购买,Palisade Bio Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Palisade Bio Inc.(PALI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Palisade Bio Inc.(PALI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction